Description: IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.
Home Page: www.iqvia.com
IQV Technical Analysis
4820 Emperor boulevard
Durham,
NC
27703
United States
Phone:
919 998 2000
Officers
| Name | Title |
|---|---|
| Mr. Ari Bousbib | Chairman, Pres & CEO |
| Mr. Ronald E. Bruehlman | Exec. VP & CFO |
| Mr. Eric M. Sherbet | Exec. VP, Gen. Counsel & Sec. |
| Mr. Kevin C. Knightly | Pres of Corp. Strategy & Enterprise Networks |
| Ms. Keriann Cherofsky | Sr. VP, Corp. Controller & Principal Accounting Officer |
| Dr. Jeffrey A. Spaeder | Sr. VP, Global Chief Medical & Scientific Officer |
| Mr. Karl Guenault | Sr. VP & Chief Information Officer |
| Andrew Markwick | Sr. VP of Investor Relations |
| Mr. Nicholas Childs | Sr. VP, Investor Relations & Corp. Communications |
| Ms. Trudy Stein | Chief HR Officer & Exec. VP |
Exchange: NYSE
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 18.5874 |
|---|---|
| Trailing PE: | 33.9008 |
| Price-to-Book MRQ: | 7.2438 |
| Price-to-Sales TTM: | 2.7057 |
| IPO Date: | 2013-05-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 85000 |